Novo Nordisk filed a lawsuit in a South African high court against local compounding pharmacy iDexis. The pharmaceutical giant seeks an injunction to halt the manufacturing and sale of unauthorized semaglutide versions. Semaglutide serves as the active ingredient in the company's Wegovy and Ozempic treatments.
Novo Nordisk classifies the iDexis products as unregistered and untested. The requested injunction would stop distribution pending a final court ruling.
This litigation aims to protect market-leading obesity treatments from unregulated competition. The broader GLP-1 drug market for weight loss and diabetes continues to expand rapidly as new competitors attempt to enter the sector.